Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes  by Szabó-Taylor, Katalin É. et al.
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a  b  s  t  r  a  c  t
Peroxiredoxin  2  has immune  regulatory  functions,  but its expression  in  human  peripheral  blood  lym-
phocytes  and  levels  in extracellular  ﬂuid  in  healthy  subjects  and  rheumatoid  arthritis  patients  are poorly
described.  In the  present  study,  the  median  intracellular  peroxiredoxin  2 protein  content  of  lymphocytes
from  rheumatoid  arthritis  patients  was more  than  two-fold  higher  compared  with  healthy  subjects’
lymphocytes.  Intracellular  peroxiredoxin  3 levels  were  similar  in healthy  and  rheumatoid  arthritis  lym-
phocytes.  Flow  cytometry  detected  peroxiredoxin  2  on the surface  of  ca. 8% of T cells  and  ca.  56%  of
B cells  (median  % values)  of all subjects  analyzed.  Exofacial  thioredoxin-1  was  also  observed.  In thenterleukin 17
ell surface
utoimmune disease
eroxiredoxin
hioredoxin
total  lymphocyte  population  from  rheumatoid  arthritis  patients,  few cells  (median,  6%) displayed  sur-
face peroxiredoxin  2. In contrast,  a signiﬁcantly  increased  proportion  of  interleukin-17+ve lymphocytes
were  exofacially  peroxiredoxin  2+ve (median,  39%).  Prdx2  was  also  detected  in human  extracellular  ﬂu-
ids. We  suggest  that  crucial  inﬂammatory  cell  subsets,  i.e. interleukin-17+ve T cells, exhibit  increased
exofacial  redox-regulating  enzymes  and  that peroxiredoxin  2  may  be involved  in  the  persistence  of
 chropro-inﬂammatory  cells  in
. Introduction
Peroxiredoxins (Prdxs) are important antioxidant enzymes.
hey function as thioredoxin peroxidases, with six mammalian
sozymes (Prdxs 1–6). Typical 2-Cys Prdxs (Prdxs 1–4) use a redox-
ctive cysteine residue, termed the peroxidatic cysteine, to reduce
ydrogen peroxide (H2O2) (Wood et al., 2003b). This residue is
ubsequently reduced to a thiol (Cys-SH) when a resolving cys-
eine (Cys-SH) residue attacks the peroxidatic cysteine (Cys-SOH),
orming an inter-subunit disulﬁde bond which is then reduced
y thioredoxin (Trx) (Wood et al., 2003b). Trx is maintained in
Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; ECL, enhanced chemilu-
inescence; HS, healthy subjects; EDTA, ethylenediaminetetraacetic acid; TLR4,
oll-like receptor 4; OA, osteoarthritis; PBLs, peripheral blood lymphocytes; PBMCs,
eripheral blood mononuclear cells; PE, phycoerythrin; Prdx, peroxiredoxin; Q-RT-
CR, quantitative real-time polymerase chain reaction; RA, rheumatoid arthritis;
BS, phosphate buffered saline; ROS, reactive oxygen species; RT-PCR, reverse
ranscription polymerase chain reaction; Srx, sulﬁredoxin; Trx, thioredoxin; TrxR,
hioredoxin reductase.
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E-mail address: paul.winyard@pms.ac.uk (P.G. Winyard).
357-2725 © 2012 Elsevier Ltd. 
ttp://dx.doi.org/10.1016/j.biocel.2012.04.016
Open access under CC BY-NC-ND license.nic  inﬂammation.
© 2012 Elsevier Ltd. 
a reduced state by virtue of the activity of thioredoxin reductase
(TrxR) (Arner and Holmgren, 2000). Besides acting as antioxidants,
Prdxs have cell signaling roles (Kang et al., 2005), partly due to their
susceptibility to “overoxidation” whereby the sulfenic acid reaction
intermediate is oxidized to sulﬁnic acid by H2O2, allowing a local,
transient, increase in H2O2 concentration (Wood et al., 2003a).
Prdxs 1–4 use sulﬁredoxin (Srx) or sestrins as electron donors for
the reduction of their sulﬁnic acid form to sulfenic acid (Biteau et al.,
2003; Budanov et al., 2004). Prdx2 is a modulator of inﬂammatory
and immune responses, probably through its antioxidant activity
(Szabó et al., 2009).
Rheumatoid arthritis (RA) is an autoimmune disorder which
affects about 1–2% of the population worldwide (Hakim et al.,
2006). Although RA primarily affects synovial joints, it is a sys-
temic disease, and Th1 and Th17 (IL-17+ve) lymphocytes have been
implicated in RA pathogenesis (Annunziato et al., 2009). Key fea-
tures of the disease are chronic inﬂammation, oxidative stress
and dysfunctional apoptosis. The overproduction of reactive oxy-
Open access under CC BY-NC-ND license.gen species (ROS) leads to the exhaustion of some antioxidants
(Gilston et al., 1998; Pattison and Winyard, 2008). Oxidative dam-
age within the peripheral blood lymphocytes (PBLs) in RA patients
is demonstrated by an increase in the levels of the mutagenic
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-hydroxydeoxyguanosine in lymphocyte DNA compared with
ealthy control subjects (Bashir et al., 1993). Chronic exposure
f lymphocytes to oxidative stress is associated with resistance
o apoptosis (Brown and Bicknell, 2001), and defective apoptosis
s a feature of a number of inﬂammatory autoimmune diseases
Eggleton et al., 2010; Tarr et al., 2010). The lack of apoptotic clear-
nce of inﬂammatory immune cells has been implicated in the
hronicity of inﬂammation in RA (Liu and Pope, 2003). Both Prdx2
nd Prdx3 are inhibitors of apoptosis (Zhang et al., 1997), and there-
ore these Prdxs may  regulate the removal of inﬂammatory cells.
Despite the above indirect evidence that Prdxs might be
nvolved in RA pathogenesis, direct evidence is limited, although a
mall number of studies have examined the role of Trx1. Serum and
ynovial ﬂuid Trx1 levels were elevated in RA patients compared
ith osteoarthritis (OA) patients and healthy subjects (HS), and
lasma and synovial ﬂuid Trx1 concentrations correlated with dis-
ase activity and progression (Jikimoto et al., 2001; Maurice et al.,
999). Furthermore, treatment of human synovial ﬁbroblast cul-
ures with Trx1 augmented IL-1 and IL-6 production upon TNF-
timulation (Yoshida et al., 1999). These results support the idea
hat Trx1 is pro-inﬂammatory. However, information on the role in
A of Prdxs – as redox partners of Trx1 – remains scant. The aim of
he present study was to investigate the potential role of intracel-
ular and exofacial Prdx2 – along with selected other members of
he Prdx-based system – in peripheral blood lymphocytes from RA
nd HS.
. Materials and methods
.1. Materials
Recombinant human Prdx2 and Prdx3 were obtained from
bFrontier (Seoul, South Korea), and Trx1 was a gift of Dr Kamal
amidi (University of Exeter). Mouse monoclonal and rabbit poly-
lonal anti-human antibodies to Prdx2 (1E8, 9A1), Prdx3 (4G10),
veroxidized Prdx (10A1) and Trx1 (8A1) were from AbFrontier.
orseradish peroxidase (HRP)-conjugated goat anti-rabbit anti-
ody was from Abcam (Cambridge, UK). The HRP-conjugated goat
nti-mouse antibody and the monoclonal anti-human -tubulin
TUB2.1) antibody were from Sigma (Dorset, UK). Fluorescein
sothiocyanate (FITC)-conjugated goat anti-mouse or anti-rabbit
gG secondary antibodies were from Beckman-Coulter (High
ycombe, UK). FITC-conjugated goat anti-mouse Fab2 antibody
as from Jackson ImmunoResearch Laboratories (Suffolk, UK).
Phycoerythrin (PE)-conjugated anti-human CD3 and PE-
onjugated anti-human CD19 antibodies were from Biolegend (San
iego, USA). FITC-conjugated mouse and rabbit IgG1 isotype con-
rol antibodies were from Santa Cruz Biotechnology (Santa Cruz,
SA) and a FITC-conjugated mouse IgG1  isotype control antibody
MOPC21) was from BD Pharmingen (Pecs, Hungary). ProLong®
old Antifade Reagent with 4′,6-diamidino-2-phenylindole (DAPI)
as from Invitrogen (Budapest, Hungary). Ficoll-Paque Plus was
rom GE Healthcare (Amersham, UK) and Histopaque-1077 was
rom Sigma (Budapest, Hungary). Cell culture reagents such as RPMI
ulture medium, fetal bovine serum and penicillin-streptomycin
ere from Lonza (Wokingham, UK). NP40 lysis buffer and Magic
arker molecular mass markers were purchased from Invitrogen
Paisley, UK). The Bradford reagent was from Sigma. Commer-
ially prepared 4–20% gradient SDS-PAGE gels were obtained
rom Thermo Fisher Scientiﬁc (Northumberland, UK). PVDF mem-
ranes and 30% acrylamide were purchased from Bio-Rad (Hemel
empstead, UK). The Quantichrom Hemoglobin Assay was from
ioAssay Systems (Hayward, USA). CytoStim T cell stimulant
nd the IL-17 secretion assay were supplied by Miltenyi Biotec
Bisley, UK).chemistry & Cell Biology 44 (2012) 1223– 1231
2.2. RA and healthy subjects
RA patients attending the outpatient clinics of the Royal Devon
and Exeter Foundation Trust Hospital (Exeter, UK) were asked to
take part in the study. All patients and HS gave written consent and
the study was authorized by the North and East Devon Research
Ethics Committee. In total, 45 patients with diagnosed RA based on
the 1987 American College of Rheumatology criteria for RA (Arnett
et al., 1988) were recruited for various aspects of the study. EDTA
anti-coagulated blood samples (up to 40 ml) were obtained from
all subjects. Plasma was obtained by centrifugation of EDTA anti-
coagulated blood samples at 1611 × g for 10 min at RT. Synovial
ﬂuid samples from RA patients were obtained during routine knee
aspirations. Due to the relatively large volumes of blood needed
to perform all the assays in replicate, it was not possible to use
the same patients for all of the analyses used in this study. For full
details of the volunteers, see Supplementary Data 1.
2.3. Peripheral blood lymphocyte isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from
EDTA anticoagulated whole blood of RA patients and HS using
Ficoll-Paque PlusTM or Histopaque-1077, according to the manu-
facturer’s instructions. Any residual red blood cell contamination
was removed by hypotonic lysis. In order to eliminate platelets and
monocytes and obtain a pure fraction of PBLs, PBMCs were cultured
overnight at 37 ◦C in 5% CO2/air in RPMI culture medium supple-
mented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin and
100 g/ml streptomycin.
2.4. Western blotting
Cell lysis was performed using NP40 lysis buffer according to the
manufacturer’s instructions. Brieﬂy, lysis buffer was  added to the
cell pellets, followed by 30 min  incubation on ice with intermittent
vortexing, and ﬁnally by centrifugation at 10,000 g for 10 min. Pro-
tein concentrations of the samples were measured by the Bradford
assay. Protein lysates (30 g), molecular mass markers and puri-
ﬁed recombinant Prdx2, Prdx3 and Trx1 were separated on 4–20%
reducing or non-reducing SDS-PAGE gels, transferred onto PVDF
membranes, incubated with 1:2000 (0.5 g/ml) primary mouse
monoclonal anti-human antibodies to Prdx2, Prdx3, overoxidized
Prdx, or Trx1, followed by incubation with HRP-conjugated goat
anti-mouse secondary antibody at 1:2000 dilution and detection by
enhanced chemiluminescence (ECL) using a Chemidoc XRS imager
system (Bio-Rad). Tubulin bands resolved on separate reducing
blots were used as a loading control, and bands showing unequal
loading were excluded from the analysis. Densitometry analysis
was performed using Quantity One 1-D analysis software (Bio-Rad).
2.5. Reverse transcription PCR (RT-PCR) and quantitative
real-time PCR (Q-RT-PCR)
mRNA was extracted from RA (n = 8) and HS (n = 8) lymphocytes
and RT-PCR of Prdxs 1–6 was performed as described (Lehtonen
et al., 2004a). mRNA was  extracted from additional RA (n = 19) and
HS (n = 13) lymphocytes, from which cDNA was synthesized for
subsequent Q-RT-PCR analysis. The expression of selected genes
(Prdxs 2, 3, 5, Srx, Trx1 and TR) was quantiﬁed using Q-RT-PCR using
our previously published methods (Eggleton et al., 2010; Tarr et al.,
2010).2.6. Flow cytometry analysis of exofacial Prdx2 and Trx1
PBLs (isolated as described above) were dispensed at a density of
0.2 × 106 cells per 100 l cold buffer (PBS supplemented with 0.5%
 of Biochemistry & Cell Biology 44 (2012) 1223– 1231 1225
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Fig. 1. A representative Western blot of the intracellular expression of Prdx2 in
blood lymphocyte lysates from RA patients compared with healthy subjects. Lysates
of  lymphocytes from RA patients and healthy subjects (HS) were loaded (30 g total
protein/lane) onto 4–20% gradient SDS-PAGE gels under non-reducing conditions
and analyzed by Western blotting with anti-Prdx2. Molecular mass markers are
denoted by ‘M’. Samples of puriﬁed human Prdx2 (10, 25 and 100 ng/lane) were
loaded as standards on each blot. Equal loading of total protein was  conﬁrmed by
the  Bradford assay and aliquots of the lysates were resolved on SDS-PAGE under
ples (Fig. 2). Prdx3 was  resolved as a dimer on non-reducing blots
(RA: n = 6, healthy: n = 6), indicating that the majority of Prdx3 was
in the reduced state in the cells. Slight monomeric bands were
also visible in most samples, potentially showing some overoxi-
Fig. 2. A representative Western blot of the intracellular expression of Prdx3 in
blood lymphocyte lysates from RA patients compared with healthy subjects. Lysates
of  lymphocytes from RA patients and healthy subjects (HS) were loaded (30 g total
protein/lane) onto 4–20% gradient SDS-PAGE gels under non-reducing conditionsK.É. Szabó-Taylor et al. / The International Journal
w/v) bovine serum albumin and 2 mM EDTA) in sterile Eppendorf
ubes. The cells were incubated with 5 g/ml mouse monoclonal
r rabbit polyclonal primary antibody to Prdx2 or Trx1 for 15 min
n ice. Subsequently, the cells were washed twice in PBS and
ncubated in 100 l cold buffer containing 0.25 l FITC-conjugated
oat anti-mouse or anti-rabbit IgG secondary antibody. Following
5 min  incubation on ice and two washing steps, the cells were
ncubated for 30 min  with 5 l PE-conjugated anti-human CD3
r PE-conjugated anti-human CD19 – T and B lymphocyte mark-
rs, respectively. The following controls were also used: unstained
ells, cells stained with FITC-conjugated secondary antibody only,
ells treated with PE-conjugated anti-CD3 and, ﬁnally, cells treated
ith a FITC-conjugated mouse or rabbit IgG1 as an isotype control.
amples were analyzed on a Cell Lab Quanta SC ﬂow cytometer
Beckman Coulter, High Wycombe, UK).
.7. Fluorescence microscopy of intracellular and exofacial Prdx2
nd Trx1 in peripheral blood lymphocytes
PBLs were isolated as described above and resuspended in
locking buffer (PBS containing 0.5% (w/v) bovine serum albumin
nd 2 mM EDTA) at 2 × 106 cells/ml density. Samples for intracel-
ular staining were subsequently pelleted and permeabilized by
ncubation in methanol for 20 min  at −20 ◦C, followed by wash-
ng and resuspension in blocking buffer at the indicated density.
liquots (100 l) of the cells were then incubated for 15 min  on
ce with 0.5 l mouse monoclonal antibody to Prdx 2, Trx 1 or
 l FITC-conjugated mouse IgG1  isotype control antibody. This
as followed by washing and incubation for 15 min  on ice with
.75 l of a FITC-labeled goat anti-mouse Fab2 antibody. The cells
ere subsequently washed and mounted on microscopy slides as
escribed below.
Cells for exofacial staining were used live, at the indicated den-
ity. Aliquots of the live cells (100 l, containing 0.2 × 106 cells)
ere incubated for 30 min  on ice with 2.5 l mouse monoclonal
ntibody to Prdx 2 or Trx 1. This was followed by washing and
ncubation on ice for 15 min  with 0.25 l of a FITC-labeled goat
nti-mouse Fab2 antibody. An aliquot stained with the secondary
ntibody only was used as a negative control. After washing, the
ells were ﬁxed using 4% paraformaldehyde.
The stained and ﬁxed cells were subjected to cytospin, washed
sing PBS, then mounted on the slide by adding a drop of Pro-
ong Gold Antifade Reagent with DAPI and covering the drop
ith a coverslip. Images were taken using a Nikon H600L ﬂu-
rescence microscope equipped with a SpotFlex FX1520 digital
amera.
.8. T cell stimulation and assay of IL-17 secretion
After isolation from peripheral blood, PBMCs were maintained
vernight, at 1.5 × 106 cells/well in 96 well plates in RPMI medium
upplemented with 5% (v/v) autologous serum, in 5% CO2/air at
7 ◦C. A sensitive secretion assay was used to detect IL-17-secreting
ells, according to the instructions of the manufacturer (Miltenyi
iotec). In this assay, T cells were stimulated by incubation for 4 h
ith CytoStim, a superantigen T cell stimulant (used at 20 l/ml
edium). The IL-17-secreting cells were labeled according to the
anufacturer’s instructions, and this step was followed by label-
ng with an anti-Trx1 or anti-Prdx2 rabbit polyclonal antibody and
 FITC-conjugated anti-rabbit secondary antibody. Unstimulated
ells were collected, to serve as negative controls. Stimulated and
nstimulated cells from RA patients (n = 3) were also used for RNA
xtraction and subsequent Q-RT-PCR analysis of Prdx2 levels as
escribed above.reducing conditions, blotted and probed with anti-tubulin. The bands in this tubulin
blot image originate from two blots and have been moved around to match the order
of  samples in the Prdx2 blot.
2.9. Statistical analysis
Pair-wise differences between mRNA, intracellular and cell
surface protein levels between groups were tested using a
Mann–Whitney U-test. Correlations between mRNA/protein levels
and clinical parameters were tested using Spearman’s rank corre-
lation coefﬁcient (rs).
3. Results
3.1. Intracellular protein levels of Prdx2, Prdx3 and Trx1 in RA
subjects compared to healthy subjects
Lymphocyte cell lysates from RA patients (n = 10) and healthy
subjects (n = 9) were analyzed by non-reducing gradient SDS-PAGE
and immunoblotted for Prdx2 (Fig. 1) and Prdx3 (Fig. 2). Non-
reducing blots were used in order to reveal if the Prdxs were present
in the overoxidized form in these samples: upon cell lysis, reduced
Prdxs oxidize and form dimers, whereas overoxidized Prdxs are
unable to dimerize and resolve as monomers on non-reducing
blots (Peskin et al., 2007). On non-reducing gels, Prdx2 in all sam-
ples exhibited an oligomeric mobility corresponding to a dimer.
The monomeric band (22 kDa) was not detectable in most cases
(Fig. 1), indicating that the majority of Prdx2 was not overoxi-
dized in these lysates. Prdx2 protein content was elevated in the RA
samples compared with HS (Mann–Whitney U-test, p < 0.05) (see
Supplementary Data 2, Supplementary Fig. 1).
Prdx3 protein was  also expressed in all lymphocyte lysate sam-and analyzed by Western blotting with anti-Prdx3. Molecular mass markers are
denoted by ‘M’. Samples of puriﬁed human Prdx3 (10, 50 and 100 ng/lane) were
loaded as standards on each blot. Equal loading of total protein was  conﬁrmed by
the  Bradford assay and aliquots of the lysates were resolved on SDS-PAGE under
reducing conditions, blotted and probed with anti-tubulin.
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level corresponding to Prdx2 was measured by Q-RT-PCR in226 K.É. Szabó-Taylor et al. / The International Journal
ized Prdx3. Prdx3 content was very similar in the RA and healthy
amples (see Supplementary Data 2).
Having obtained initial evidence from the above non-reducing
lots of Prdx2 and Prdx3, that these Prdxs were not extensively
veroxidized to cysteine sulﬁnic acid, we wished to conﬁrm this
nding by probing blots with a monoclonal antibody that recog-
izes the overoxidized forms of Prdxs 1–4. Non-reducing blots
f lymphocyte lysate samples (RA: n = 6 and healthy: n = 6) were
robed. Lysates of Jurkat cells treated for 10 min  with H2O2
200 M,  2 mM)  were used as positive controls in the experiment
Baty et al., 2005). Although the positive controls displayed a sin-
le band (between 20 and 30 kDa, where overoxidized forms of
rdx 1–4 are expected to appear), the RA and healthy lymphocyte
ysates gave weak bands, or no bands at all (data not shown), indi-
ating that Prdx overoxidation did not occur to a large extent in
ntreated human peripheral blood lymphocytes, or that recycling
f overoxidized Prdxs was  very efﬁcient in these cells. Overoxi-
ation of Prdxs in intact human lymphocytes was nevertheless
nducible using 200 M H2O2 for 10 min  (data not shown).
Western blots of reducing SDS-PAGE were prepared, in order
o detect total Trx1 protein expression in lymphocytes from RA
atients (n = 6) and healthy subjects (n = 7). Trx1 was expressed in
ll analyzed subjects (data not shown), at similar levels in the RA
n = 6) and healthy groups (n = 7).
.2. Relative mRNA levels of the Prdx-based gene family in
solated lymphocytes from healthy individuals and RA patients
Having observed differences in Prdx 2 but not Prx3 at the pro-
ein level in lymphocytes from RA patients compared to healthy
ubjects, we investigated whether there were differences in the
rdx-based gene family at the mRNA level. RT-PCR analysis (RA:
 = 8, HS: n = 8) showed that all six Prdxs were expressed in PBLs,
oth in RA patients and healthy subjects. PBLs from additional RA
n = 19) and healthy (n = 13) subjects were used for Q-RT-PCR anal-
sis of Prdx2, Prdx3, Prdx5, Srx, Trx1 and TR 1. These members of
he Prdx-based family were selected for the following reasons: Srx,
rx1 and TR 1 are reducing partners of Prdx2 (Szabó et al., 2009).
rdx3 is a mitochondrial Prdx and has anti-apoptotic functions (Cox
t al., 2008), and could therefore be relevant in RA where a failure
f apoptosis of inﬂammatory cells contributes to disease pathology
see Section 1). Finally, Prdx5 over-expression has been shown in
A (Wang et al., 2002). Employing Q-RT-PCR, we found that all of
he mentioned six genes were expressed in all subjects. However,
here were no signiﬁcant differences in gene expression between
ndividual genes in RA and HS subjects (data not shown). A strong
ositive correlation was present between Trx1 protein and Trx1
RNA levels (rs = 0.94; p < 0.0001; n = 13). In contrast, we  did not
bserve signiﬁcant correlations between protein and mRNA levels
f Prdx2 and Prdx3 in lymphocytes.
Disease duration showed a positive correlation with Prdx2
RNA expression levels (rs = 0.68, p = 0.01, n = 13). In the RA group,
here was a negative correlation between age, and (a) the level
f Srx mRNA (rs = −0.55, p = 0.02, n = 19) and (b) the level of TR
RNA (rs = −0.50, p = 0.03, n = 19). No signiﬁcant correlations were
bserved between age and the relative mRNA expression of Prdx2,
rdx3, Prdx5, Srx, Trx1, or TR1 in the healthy group.
.3. Prdx2 and Trx1 are both present on the surface of human
ymphocytes and are differentially displayed in lymphocyte
ubpopulationsExofacial Prdx2 and Trx1 were both present on human B and
 lymphocytes, as detected by ﬂow cytometry. CD3 was  used as
 marker of T cells and CD19 was used as a marker of B cells.
rdx2 was displayed on both CD3+ve and CD19+ve cells (Fig. 3A),chemistry & Cell Biology 44 (2012) 1223– 1231
and the proportion of CD19+ve cells displaying Prdx2 was  signiﬁ-
cantly higher compared with CD3+ve cells, in both the healthy and
the RA group (Fig. 3B). In the healthy group (n = 5), 59% [median %]
(range 54–81%) of CD19+ve cells were positive for Prdx2 staining,
whereas only 8% [median %] (range 7–17%) of CD3+ve cells were pos-
itive for Prdx2 (p < 0.01). In the RA group (n = 5), 51% (range 38–71%)
of CD19+ve cells exhibited positive staining for Prdx2, whereas only
6% (range 5–10%) of CD3+ve cells were positive for Prdx2 staining
(p < 0.01).
The median expression of Trx1 on CD3+ve lymphocytes (T cells)
was 3% in the healthy (n = 5, range: 2–9%) and 4% in the RA group
(n = 5, range: 3–9%; Fig. 3C). The proportion of CD19+ve cells (B
lymphocytes) displaying Trx1 was signiﬁcantly higher (p < 0.01)
than the proportion of CD3+ve T cells displaying Trx1: Trx1 was
present on 62% and 71% (median values) of all CD19+ve cells in the
healthy group (n = 5, range: 48–79%) and RA group (n = 5, range:
43–83%), respectively (Fig. 3C). To conﬁrm the exofacial pres-
ence of Prdx2 and Trx1, immunocytochemistry was  performed
on non-permeabilized PBLs (Fig. 3D; panels a–i), using a FITC-
conjugated goat anti-mouse Fab2 antibody as a negative control
(panels a–c) and antibodies against Prdx2 (panels d–f) and Trx1
(panels g–i) in conjunction with a FITC-conjugated goat anti-mouse
Fab2 antibody. We  also examined permeabilized lymphocytes for
intracellular Prdx2, using anti-Prdx2 (panels j–l) in conjunction
with a FITC-conjugated goat anti-mouse Fab2 antibody. Exofa-
cial localization of both Trx1 and Prdx2 was observed (shown by
arrows in panels i and f, respectively). Intracellular Prdx2 appeared
more abundant within lymphocytes (shown by arrows in panel
l). There was no detection of non-speciﬁc binding to cells of the
FITC-conjugated goat anti-mouse Fab2 (panel c, merged image).
3.4. The proportion of IL-17-secreting RA lymphocytes displaying
exofacial Prdx2 is increased compared with the total RA
lymphocyte population
IL-17-secreting T cells were detected using a ﬂow cytometry
IL-17 capture assay in the blood lymphocyte population from RA
(n = 6) and healthy (n = 6) subjects. As expected, the percentage of
IL-17-secreting cells within the total lymphocyte population was
signiﬁcantly higher (Mann–Whitney U-test, p < 0.005) in the RA
group (median: 0.46%, range: 0.3–1.3%) than in the healthy group
(median: 0.08%, range: 0–0.27%; Fig. 4A). A subset of the general
lymphocyte population displayed Prdx2 (Fig. 4B) and Trx1 (Fig. 4C)
on their surface. Due to the extremely small number of IL-17-
secreting PBLs in the healthy samples, only the RA samples were
used to estimate the percentage of Prdx2+ve IL17+ve and Trx1+ve
IL17+ve cells. Prdx2 was displayed on 36–57% (median: 39%) of IL-
17-secreting PBLs (Fig. 4B), while Trx1 was displayed on 3–53%
(median: 44%) of IL-17-secreting PBLs in the RA patients screened
(Fig. 4C). The median percentage of Prdx2+ve cells in the IL-17-
secreting population, was signiﬁcantly greater (p < 0.005) than the
median percentage of Prdx2+ve cells in the total lymphocyte pop-
ulation (Fig. 4B). There was no statistically signiﬁcant difference
in the median percentage of Trx1+ve cells in the IL-17-secreting
population compared with the total PBL population (Fig. 4C).
Remarkably, the median proportion of all lymphocytes (i.e.
the total lymphocyte population-not the IL-17+ve cells only)
exhibiting Prdx2 on their surface increased signiﬁcantly after
stimulation with CytoStim for 4 h in RA patients (p < 0.005,
Mann–Whitney U-test) (Supplementary Fig. 2B). The mRNARA PBLs (n = 3) before and after stimulation, but no evidence
was found of an increase in Prdx2 production at the mRNA
level following stimulation with CytoStim for 4 h (data not
shown).
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Fig. 3. Presence of exofacial Prdx2 and Trx1 on lymphocytes. (A) Representative ﬂow cytometry dot plots of the presence of exofacial Prdx2 and Trx1 on T and B lymphocytes.
The  Y-axes show the proportion of lymphocytes with a T cell (CD3-PE) or B cell (CD19-PE) phenotype. The X-axes show the proportion of lymphocytes that stain for cell
surface  Trx1 (Trx1-FITC indirect staining) or Prdx2 (Prdx2-FITC indirect staining). Thus the upper right-hand quadrant of each graph shows the proportion of T or B cells
that  stain for Trx1 or Prdx2. The numbers in each graph represent the percentage of cells contained in each quadrant. (B) The % of T and B lymphocytes in RA and healthy
(HS)  lymphocytes with exofacial Prdx2 is shown. Horizontal lines indicate median values. Two asterisks indicate a statistically signiﬁcant difference at the p < 0.01 level
(Mann–Whitney U-test). (C) The % of T and B lymphocytes in RA and healthy (HS) lymphocytes with exofacial Trx1 is shown. Horizontal lines indicate median values. Two
asterisks indicate a statistically signiﬁcant difference at the p < 0.01 level (Mann–Whitney U-test). (D) Immunohistochemical detection of exofacial Prdx2 and Trx1, and
intracellular Prdx2 in peripheral blood lymphocytes from a healthy subject. PBLs were isolated from peripheral blood. Exofacial Prdx2 (panel e) and Trx1 (panel h) was
detected on live cells using mouse monoclonal antibodies to human Prdx2 and Trx1, respectively, in conjunction with a FITC-conjugated goat anti-mouse Fab2 fragment of
IgG.  Cells labeled with the secondary antibody only were used as controls (panels a–c). After labeling, the cells were ﬁxed with 4% paraformaldehyde and mounted on slides
with  antifade ﬂuid supplemented with DAPI for nuclear staining (panels a, d, g). Cells permeabilized and ﬁxed with methanol were used to label intracellular Prdx2 (panel k).
The  permeabilized and labeled cells were mounted on slides with antifade ﬂuid supplemented with DAPI for nuclear staining (panel j). The arrows in panels f, i, and l depict
DAPI-stained cells that were positive for exofacial Prdx2 (panel f), exofacial Trx1 (panel i), or intracellular Prdx2 (panel l), respectively.
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Fig. 4. Percentages of lymphocytes from healthy subjects (HS) and RA patients (RA) that were positive for IL-17 secretion and exofacial Prdx2 and Trx1, as determined by ﬂow
cytometry. See “Section 2” for details. (A) Percentages of IL-17-secreting cells within the total lymphocyte population in healthy subjects and in RA patients. (B) Comparison
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. Discussion
The present study showed that Prdx2, Prdx3 and Trx1 were all
resent, at the protein level, in peripheral blood lymphocytes from
oth healthy human subjects and RA patients. Semi-quantitative
nalysis of western blots suggested that the lymphocyte content of
rdx2 – but not two related proteins, Prdx3 and Trx1 – was  elevated
n RA patients. Not only was Prdx2 protein content elevated in RA
ymphocytes in the peripheral circulation but intracellular Prdx2
evels were in positive correlation with the serum concentrations
f CRP, an inﬂammatory marker. This suggests the possibility that
rdx2 may  be elevated as part of the inﬂammatory response in
A lymphocytes, and is reminiscent of the well-known induction
f plasma Trx1 during the inﬂammatory response in RA (Jikimoto
t al., 2001). Although Prdx2 in RA blood lymphocytes, plasma
nd synovial ﬂuid has not been studied before, previous studies
Bo et al., 2009; Kim et al., 2006) showed that Prdx2 protein was
levated in the synovial tissue of RA patients compared with the
ynovial tissue from OA patients, and Prdx2 was also elevated in
ultured RA and OA synovial ﬁbroblasts compared with healthy
ontrol ﬁbroblasts.
Prdx2 is a redox enzyme with extensive roles in immune regu-
ation: Prdx2 knockout mice suffer from the expansion of certain
mmune cell populations (Moon et al., 2006) and intracellular Prdx2
s a negative regulator of the pro-inﬂammatory toll-like receptor 4
TLR4) signaling pathway (Yang et al., 2007). At the same time, by
onsuming H2O2, Prdx2 contributes to the sustenance of the mito-
en activated protein kinase kinase/extracellular signal-regulated
inase pathway of T cell receptor signaling (Kwon et al., 2003).
oreover, Prdx2 is an inhibitor of apoptosis (Zhang et al., 1997).
herefore, it is unclear whether the observed increase in the intra-
ellular Prdx2 content of the peripheral blood lymphocytes from RA
atients plays a pathological or protective role. However, a reducing
nvironment intracellularly in lymphocytes is necessary to main-
ain levels of extracellular thiols, which in turn are necessary foropulation in RA patients. (C) Comparison of the percentages of Trx1+ve cells within
(B), three asterisks indicate a statistically signiﬁcant difference at the p < 0.005 level
the functioning of T helper cells (Grifﬁths et al., 2011). Therefore, it
is possible that by maintaining a reducing environment, the Prdx
system contributes to T cell activation in RA.
In the current study, immunoblots of non-reducing gels of
lysates from healthy and RA lymphocytes showed the presence of
Prdx2 and Prdx3 dimers, with only weak monomeric bands, indi-
cating that the majority of the Prdx2 and Prdx3 molecules were
not overoxidized (Figs. 1 and 2). Moreover, when probed with
a speciﬁc antibody to the overoxidized conserved site cysteine
residue of peroxiredoxins, blots revealed no detectable staining for
the overoxidized forms of Prdx2 or Prdx3. The lack of large-scale
overoxidation of Prdxs may  indicate that the enzymes were redox
active in these samples.
The expression of mRNA for Prdxs 1–3 in different mammalian
tissues appears ubiquitous (Chae et al., 1999). Nevertheless, few
systematic studies have been performed describing their expres-
sion, particularly in a clinical setting. To our knowledge, this is the
ﬁrst study to demonstrate that all six Prdxs are expressed in human
lymphocytes, at least at the mRNA level. Previously, it has been
observed that the cellular mRNA and protein levels of the Prdxs do
not necessarily correlate with each other (Lehtonen et al., 2004b;
Seo et al., 2000) indicating that post-transcriptional mechanisms
may  play important roles in modulating Prdx protein levels. In the
present study, we found no relationship between the amount of
Prdx2/3 mRNA and the corresponding protein levels. Thus there
was no difference in lymphocyte Prdx2 mRNA levels between RA
patients and healthy subjects, despite the elevated Prdx2 protein
content of RA lymphocytes.
The presence of exofacial Trx1 is well known on a wide range of
human cells (Wollman et al., 1997; Martin and Dean, 1991; Sahaf
et al., 1997), and has been suggested to play a role in cell adhe-
sion during the inﬂammatory response (Hara et al., 2007). To date,
the presence of exofacial Prdx2 has not been described in higher
eukaryotes. However, in the protozoan, Entamoeba histolytica,  a
29 kDa Prdx, assumed to protect the pathogen from oxidant attack
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Fig. 5. A basic summary of some of the major lymphocyte subsets in relation to the levels of intracellular and exofacial Prdx2. The diagram summarizes the key results found
in  the present study, comparing healthy subjects with RA patients. For simplicity, a number of subtypes of T cell have been omitted from the ﬁgure. Prdx2 is schematically
shown  as a red ring, representing the crystal structure of the decameric human red blood cell Prdx 2 (Schröder et al., 2000). It is unknown if the exofacial Prdx2 is in the
decameric, or a different oligomeric form. Intracellular Prdx2 protein content was  elevated in RA lymphocytes compared with lymphocytes from healthy subjects. The median
proportion of B cells displaying exofacial Prdx2 and Trx1 was  higher compared with Prdx2+ve and Trx1+ve T cells in both the RA and healthy subjects. The indicated values of
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 RA patients and 5 healthy subjects shown in Fig 3B). The medain proportion of Th
rdx2+ve cells in the total lymphocyte population in RA patients. (Th: T helper cell).
y the host, is the major thiol-containing surface antigen (Choi
t al., 2005). Moreover, Prdx1 was detected on the surface of a 2B4
ouse T cell hybridoma line (Metcalfe et al., 2011). In the current
tudy, the presence of Prdx2 on the cell surface of human lympho-
ytes was demonstrated for the ﬁrst time. We  also showed that
he redox-regulating enzymes Prdx2 and Trx1 were differentially
isplayed on the surface of human peripheral blood lymphocyte
ubsets. These results are schematically summarized in Fig. 5. While
 high proportion of unstimulated B cells displayed exofacial Trx1
nd Prdx2, few T cells displayed these two enzymes on the surface
nder resting conditions. These observations are in line with pre-
ious studies (Lawrence et al., 1996; Pedersen-Lane et al., 2007),
n which differences were detected between human lymphocyte
ubsets with regard to their surface thiol levels: CD19+ve cells (i.e.
 cells) had the highest surface thiol levels, followed by CD8+ve T
ells, then by CD4+ve T cells.
Surface thiols are extremely important in the regulation and
ctivity of lymphocytes. Although there is some controversy in
he literature, elevated lymphocyte surface thiol levels have been
hown to increase susceptibility to RA (Gelderman et al., 2006),
uggesting a key role for the redox regulation of exofacial thiol-
ontaining proteins in autoimmunity. Moreover, T cells from RA
atients display decreased basal ROS levels and lower ROS produc-
ion upon stimulation compared with healthy controls (Grifﬁths
t al., 2011). Although the redox regulation of immune responses ism all the analysed PBL preparations (n = 10; made up of the pooled values from the
lls displaying exofacial Prdx2 was  higher compared with the medain proportion of
complex and cell population-speciﬁc, the current view is that effec-
tor T lymphocytes need a reducing extracellular microenvironment
for their activation (Angelini et al., 2002; Yan and Banerjee, 2010).
On the contrary, regulatory T cells (Tregs) have a different capac-
ity for redox control in comparison with effector lymphocytes: e.g.
Tregs have a lowered sensitivity to oxidative stress-induced cell
death (Mougiakakos et al., 2009) which is due to an increased
production of Trx1 in these cells (Mougiakakos et al., 2011). In
the present study, there was no difference between the RA and
healthy subject groups in relation to the percentage of unstimu-
lated lymphocytes displaying exofacial Prdx2 and Trx1. However,
upon antigenic stimulation, the percentage of Prdx2+ve lympho-
cytes increased in the RA group, but not in the healthy group.
Mitogenic activation also increased surface thiol levels of T lym-
phocytes in another study (Lawrence et al., 1996). As expected,
we observed that the percentage of IL-17-secreting cells (Th17
cells) was higher in RA blood lymphocytes compared with lympho-
cytes from healthy subjects. The pro-inﬂammatory Th17 cells, have
been suggested to provoke the pathology observed in RA (Bennett,
2008). In our study, the percentage of PBLs displaying exofacial
Prdx2 (but not Trx1) was higher among the IL-17-secreting cells
than in the general lymphocyte population in RA patients (sum-
marized in Fig. 5). These results suggest that Prdx2 may  sustain
redox-mediated immunoregulatory events at the surface of speciﬁc
pro-inﬂammatory T cell subsets, such as Th17 cells. However, such
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 role for Prdx2 would clearly be dependent on the maintenance
f the activity of the enzyme, when present in the extracellular
exofacial) environment, as well as an available supply of reducing
ubstrates for Prdx2.
We detected extracellular Prdx2 in the plasma of RA and
ealthy subjects and in the synovial ﬂuid of RA patients, and
his extracellular Prdx2 did not appear to be an artefact (see
upplementary Data 4).
The effects of different drug treatments on the expression of the
rdx-based system were analyzed by Spearman’s rank correlation
here drug doses were available, or – where drug doses were not
vailable – by dividing the patients into subgroups based on the
resence or absence of a certain drug treatment and comparing
he means of analyzed parameters between the two groups. Using
hese approaches, we found no evidence for any effects of different
rug treatments on the analyzed parameters.
The clinical relevance of our ﬁndings is two-fold, as they point
o the possibility that Prdx2 may  be used as a marker of inﬂam-
ation and as a drug target. The potential of Prdx2 as a marker
f inﬂammation is supported by: (a) the observed increase in the
evels of Prdx2 protein in RA lymphocytes compared with healthy
ubject lymphocytes, (b) the correlation of intracellular levels of
rdx2 in RA lymphocytes with serum concentrations of CRP, and (c)
he higher percentage of Prdx2+ve IL17+ve lymphocytes compared
ith the Prdx2+ve total lymphocyte population in RA patients.
This study has not addressed the functional role of Prdx2 as an
nhibitor of apoptosis of inﬂammatory cells – a research subject
ctively pursued with regard to malignant cells (Wang et al., 2005).
s Prdx2 protein concentrations may  be elevated intracellularly
nd on the surface of inﬂammatory cells in RA, the role of Prdx2
hould be addressed in these cell populations in future studies,
referably in a leukocyte subpopulation-speciﬁc manner.
In summary, the present study showed that the intracellu-
ar levels of Prdx2 protein in lymphocytes were increased in RA
atients compared with healthy subjects and that the Prdx2 lev-
ls correlated with the degree of inﬂammation as indicated by
he serum CRP concentration. We  also detected exofacial Prdx2 in
solated human lymphocytes. In RA, the proportion of cells that
isplayed exofacial Prdx2 was enhanced in the Th17 population
ompared with the total lymphocyte population, suggesting the
ossibility that Prdx2 might contribute to the activation of these
ro-inﬂammatory cells.
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